Overview
Are You at Risk After a Negative Biopsy?
Research has shown that up to 30% of men with a negative or benign prostate biopsy result actually do have prostate cancer. The disease is very difficult to diagnose because a prostate biopsy samples less than 1% of the entire prostate gland, so cancer may be present in one or more small tumors in areas the biopsy needle did not sample.
If you and your urologist have concerns about undetected prostate cancer, Confirm MDX can provide more information after a negative biopsy. It works at the DNA level on the tissue from your prior biopsy, detecting abnormal DNA changes associated with prostate cancer that cannot be seen by the standard microscopic evaluation pathologists traditionally use. The result gives you and your urologist actionable information on your risk and your need for a repeat biopsy.
Who Is Eligible?
You are eligible for Confirm MDX if you have received any of these prostate biopsy results within the prior 30 months:
- Negative / benign
- HGPIN (high-grade prostatic intraepithelial neoplasia)
- Atypia (atypical glands suspicious for malignancy)
- ASAP (atypical small acinar proliferation)
- PIA (proliferative inflammatory atrophy, or lesion)
Why Choose Confirm MDX?
- Performed on tissue from your prior biopsy, so no new procedure
- Detects changes at the DNA level that a microscope cannot see
- Helps determine whether a repeat biopsy is needed